is a leading Indian pharma company with significant presence in respiratory, oncology, and HIV drugs. It reported strong revenue and profit growth, driven by global generic launches, particularly in the US and emerging markets. Cipla is renowned for affordable drug innovation and a broad R&D pipeline. While it maintains stable financials, US price pressures and regulatory risk remain.

#WatchOutFor#TechnicalViews#FundamentalViews#EquityResearch#Miscellaneous

1,058 likes·70 comments